What the FDA labels say about taking them together
Linezolid and nortriptyline
Nortriptyline's FDA label of December 4, 2024 names linezolid in its contraindications section; linezolid's label does not name nortriptyline itself but warns about its class (Tricyclic antidepressants). The nortriptyline label: “Starting Pamelor in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.”
Check it at the source: the linezolid FDA label on DailyMed (effective June 19, 2026, Hospira, Inc.); the nortriptyline FDA label on DailyMed (effective December 4, 2024).
What does the linezolid label say about nortriptyline?
Linezolid's label does not name nortriptyline itself; it warns about its class (Tricyclic antidepressants):
Linezolid label, warnings and precautionsSpontaneous reports of serotonin syndrome including fatal cases associated with the concomitant use of linezolid and serotonergic agents have been reported. Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5-HT1 receptor agonists (triptans), and opioids, including meperidine.
Linezolid label, warnings and precautionsSpontaneous reports of serotonin syndrome including fatal cases associated with the concomitant use of ZYVOX and serotonergic agents have been reported. Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5‑HT1 receptor agonists (triptans), and opioids, including meperidine.
Source: FDA drug label (Linezolid), Hospira, Inc., effective June 19, 2026 (SPL set c401f1a8-cc37-461b-bfef-f2e156629bf8), via openFDA; the full label on DailyMed
What does the nortriptyline label say about linezolid?
Nortriptyline label, contraindicationsStarting Pamelor in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome ( see WARNINGS and DOSAGE AND ADMINISTRATION ).
Nortriptyline label, warningsSerotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Pamelor, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
Source: FDA drug label (PAMELOR), SpecGx LLC, effective December 4, 2024 (SPL set e17dc299-f52d-414d-ab6e-e809bd6f8acb), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Linezolid | Nortriptyline | |
|---|---|---|
| Labeled for | Bacterial infections | Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.44 per tablet 600 mg tablet | $0.113 per capsule 10 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once